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Associations Between Changes in Quality of Life and
Survival After Lung Cancer Surgery
Axel Mo¨ller,* and Ulrik Sartipy, MD, PhD†‡
Introduction: The aim of this study was to analyze the association
between changes in quality of life and survival after lung cancer
surgery.
Methods: In a prospective population-based cohort study, quality of
life was estimated using the Medical Outcomes Study 36-Item Short
Form (SF-36) questionnaire before and 6 months after lung cancer
surgery. Cox regression models adjusting for potential confounding
factors were used to analyze the association between baseline SF-36
scores and changes in SF-36 scores and survival.
Results: A SF-36 questionnaire was distributed to 249 patients at
baseline. We excluded 79 patients with histopathology other than
primary lung cancer. Six months after surgery, 11 patients died and
18 patients did not return the questionnaire, leaving 141 patients
with data from both baseline and follow-up. The baseline SF-36
physical component summary score was significantly associated
with survival, but the baseline mental component was not. Declines
of 10% in the physical and mental component summary scores from
baseline to follow-up were associated with an 18 and 13% higher
risk of death, respectively.
Conclusions: Changes in quality of life during 6 months after
surgery for lung cancer may provide prognostic information regard-
ing survival.
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Health-related quality of life is an important outcomemeasure in clinical trials and contributes to clinical
decision making and patient information. An association
between baseline quality of life and survival has been sug-
gested for various types of cancer1,2 and after coronary artery
bypass surgery.3 Recent evidence has confirmed a strong and
independent link between self-reported pretreatment health-
related quality of life and survival in advanced non-small cell
lung cancer.4–7 Nevertheless, less is known regarding the
prognostic value of quality of life scores after surgical treat-
ment for lung cancer. We performed a prospective, popula-
tion-based cohort study to investigate health-related quality
of life at baseline and 6 months after lung surgery. The aim
was to analyze the association between changes in quality of
life and survival after lung cancer surgery.
MATERIALS AND METHODS
From April 2006 to April 2008, 249 patients scheduled
for lung surgery at Karolinska University Hospital were
included in a prospective population-based cohort study. We
excluded 79 patients with histopathology other than primary
lung cancer. Karolinska University Hospital is the only re-
ferral center for thoracic surgery in Stockholm County, serv-
ing 20% of the total population in Sweden. Health-related
quality of life was assessed with the use of the Medical
Outcomes Study 36-Item Short Form (SF-36) question-
naire.8,9 The SF-36 evaluates eight dimensions of health:
physical functioning, role limitations due to physical prob-
lems, bodily pain, vitality, general health perception, social
function, role limitations due to emotional problems, and
mental health. The scores for each domain range from 0 to
100, with higher scores indicating better health status. The
SF-36 also provides summary scales for overall physical and
mental health-related quality of life with the use of norm-
based methods10 with higher scores indicating better health
status. All patients completed the baseline SF-36 question-
naire before surgery. Six months after the operation, the
SF-36 questionnaire was mailed to the patients, and they were
asked to complete and return the questionnaire by mail. A
reminder was sent after 1 month to patients who had not
returned the second questionnaire, and a final reminder was
sent 1 month later. Clinical patient details were prospectively
collected in a study database. The study was approved by the
regional Human Research Ethics Committee, Stockholm,
Sweden (Dnr: 2006/359-31/3). Informed consent was ob-
tained from all patients.
Survival
Survival was ascertained in June 2011 by use of the
Swedish personal identity number11 and the continuously
updated national total population register.
Statistical Analyses
Continuous variables are reported as the means and the
standard deviation. Comparisons between groups were per-
formed with Fisher’s exact test for categorical variables and
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the Mann-Whitney U test for continuous variables. Cumula-
tive survival was estimated using the Kaplan-Meier method.
A two-tailed p value less than 0.05 indicated statistical
significance. Statistical analyses were performed using IBM
SPSS Statistics 19 (IBM, Armonk, NY, USA) and STATA
11.2 (Stata, College Station, TX).
Two separate analyses were performed (models 1 and 2).
First, the association between baseline SF-36 scores and
survival was analyzed for all 170 patients. Second, the asso-
ciation between changes in SF-36 scores and survival was
analyzed for the 141 patients who had completed SF-36
questionnaires both at baseline and 6 months after surgery.
To calculate score changes, the baseline SF-36 subscale score
was subtracted from the 6-month score. For the SF-36 sum-
mary scores, we calculated the fractional change, i.e., the
change in score divided by the baseline score and multiplied
by 100; thus, the change in score was expressed as a per cent
for the SF-36 summary scores. Survival time was calculated
from the date of surgery to the date of death, or June 15, 2011.
The association between baseline SF-36 scores or changes in
SF-36 scores and survival was analyzed using the Cox pro-
portional hazard model. We report hazard ratios and 95%
confidence intervals (CIs).
In model 1, we adjusted for age (continuous variable,
years), gender, comorbidities, extent of resection, tumor
stage, smoking status, and postoperative complications; in
model 2, we also included the corresponding baseline SF-36
summary or subscale score as a continuous variable to control
for confounding by the baseline value. In model 1, we present
the hazard ratio for a 1-point difference in the baseline SF-36
summary or subscale score. In model 2, however, we present
the hazard ratio for a 10% change in the SF-36 summary
scores and a 10-point change in the SF-36 subscale scores.
If the patients had any comorbidities, they were classi-
fied as “Comorbidity: Yes”; otherwise, they were classified as
“Comorbidity: No.” Comorbidity was defined as the presence
of any of the following factors: ischemic heart disease,
hypertension, congestive heart disease, diabetes mellitus, pe-
ripheral vascular disease, or cerebrovascular disease. Isch-
emic heart disease was defined as a history of angina pectoris,
myocardial infarction, or revascularization procedure (coro-
nary artery bypass surgery or percutaneous coronary inter-
vention). Hypertension was defined as a history of high blood
pressure requiring medication. Congestive heart disease was
defined as a history of heart failure or a left ventricular
ejection fraction less than 0.5. Diabetes mellitus was defined
as diabetes requiring insulin or oral anti-diabetic medication.
Peripheral vascular disease was defined as a history of clau-
dication, carotid stenosis, or abdominal aneurysm. Cerebro-
vascular disease was defined as a history of stroke or transient
ischemic attack. The extent of resection was divided into two
groups: pneumonectomy versus lobectomy/sublobar resec-
tion. Tumor stage was divided into two groups: stage I and
stage II-III. Smoking status was divided into three categories:
current, former, and never smoker. Current smoker was
defined as an active smoker or a person who had stopped
smoking within 1 year of surgery. Former smoker was de-
fined as a previous smoker who had stopped smoking more
than 1 year before surgery. Never smoker was defined as a
person who had never been an active smoker. If the patients
had any complications, they were classified as “Complica-
tion: Yes”; otherwise, they were classified as “Complication:
No.” A complication was defined as any of the following
postoperative problems: new onset atrial fibrillation, pro-
longed air leak (chest tubes in place for more than 5 days),
pneumonia, reintubation, reoperation, or a hospital stay of 8
days or more.
RESULTS
Study Population and Survival
A baseline SF-36 questionnaire was completed by 170
patients with primary lung cancer. Six months after surgery,
11 patients had died, and 18 patients did not return the
follow-up questionnaire. The patient characteristics of the
follow-up responders and nonresponders are shown in Table
1. The mean age of the total population was 67 years, and half
were women. The majority underwent lobectomy and the
most common histopathology was adenocarcinoma. Approx-
imately 40% received adjuvant radiotherapy or chemother-
apy. Two patients underwent video-assisted thoracoscopic
sublobar resection. All the other patients had a muscle-
sparing posterolateral thoracotomy. Postoperative manage-
ment included thoracic epidural analgesia. The survival at 1
year was 88% (149 at risk), at 2 years 82% (139 at risk), and
at 4 years 70% (74 at risk). After a median follow-up time of
3.7 years, 53 deaths had occurred. Survival in patients with 6
months or more follow-up time was not significantly worse
among nonresponders compared with responders (78 versus
82%, p  0.12) at 3 years.
Associations between Baseline SF-36 Scores
and Survival
The mean baseline SF-36 summary and subscale scores
are shown in Table 2. The Cox proportional hazard models
were adjusted for age, gender, comorbidities, extent of resec-
tion, tumor stage, smoking status, and postoperative compli-
cations. There was a significant association between the
baseline SF-36 physical component summary score and sur-
vival, with a hazard ratio for a 1-point increment on the 0 to
100 scale of 0.958 (95% CI 0.932 to 0.985; p  0.003). The
baseline SF-36 mental component summary score was not
significantly associated with survival (hazard ratio for a
1-point increment on the 0 to 100 scale: 1.001 (95% CI 0.979
to 1.023; p 0.932). The baseline scores on two of the SF-36
subscales were also significantly associated with survival and
are shown in Table 2.
Associations between Changes in SF-36 Scores
and Survival
The association between changes in the SF-36 sum-
mary and subscale scores and survival was analyzed among
the 141 patients who completed the SF-36 questionnaire both
at baseline and 6 months after surgery. After a median
follow-up of 4.0 years, 35 deaths had been reported. The
mean changes in the SF-36 summary and subscale scores are
shown in Table 3. The Cox proportional hazard models were
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adjusted for age, gender, comorbidities, extent of resection,
tumor stage, smoking status, postoperative complications,
and the corresponding baseline SF-36 summary or subscale
score. There was a significant association between the frac-
tional change in the SF-36 physical component summary
score and survival, with a hazard ratio for a 10% increase of
0.82 (95% CI 0.691 to 0.985; p  0.033); i.e., a 10%
reduction in the SF-36 physical component summary score
from baseline to follow-up corresponded to an 18% higher risk
of death. There was a significant association between the frac-
tional change in the SF-36 mental component summary score
and survival, with a hazard ratio of 0.87 for a 10% increase (95%
CI 0.787 to 0.973; p 0.014); i.e., a 10% reduction in the SF-36
mental component summary score from baseline to follow-up
corresponded to a 13% higher risk of death. Changes in four of
the SF-36 subscales were also significantly associated with
survival and are shown in Table 3.
DISCUSSION
There were two main findings of this prospective,
population-based cohort study of patients who underwent
thoracic surgery for primary lung cancer. First, the self-
reported health-related quality of life scores, measured before
surgery, provided prognostic information regarding long-
term survival. Second, changes in both the physical and
mental SF-36 summary scores from baseline to 6 months
after surgery were important independent risk factors for
mortality. The strong relationship between the quality of life
parameters and survival remained after adjusting for impor-
tant clinical risk factors. Although there is no consensus
regarding what constitutes a minimally important difference
in quality of life data,12,13 a 10% difference in the SF-36
summary scores is generally considered a clinically relevant
difference. Therefore, we reported the mortality risk increase
for a clinically relevant, or 10%, decrease in the physical and
mental SF-36 summary scores. A 10% decrease in the phys-
ical component summary score during the first 6 months after
surgery was associated with an 18% increase in risk of death,
and a 10% decrease in the mental component summary score
was associated with a 13% increase in risk of death. More-
over, we found significant associations between both baseline
and changes in subscale scores and survival. The strongest
association with long-term survival was found in the social
functioning subscale.
Prior research has demonstrated that pretreatment qual-
ity of life parameters have prognostic value in advanced
cancers1,2; this relationship has also been shown for advanced
lung cancer.4–7 Our study contributes to the current literature
by providing new evidence for a strong independent prog-
nostic value of quality of life measurements in patients
undergoing surgical treatment for lung cancer. Both baseline
quality of life scores and score changes during the first 6
months after surgery were predictive of long-term survival.
The strengths of this study include the longitudinal, prospec-
tive, population-based design and the high response rate, each
of which contributed to a reduction in the risk of selection
bias and improved the external validity of the results. The
data on survival status were 100% complete and accurate
because of the high-quality national Swedish total population
register. One limitation of our study is the lack of information
regarding performance status. Performance status has been
shown to be a very important prognostic factor for survival in
lung cancer.14 Nevertheless, the prognostic importance of
performance status seems to be lesser among surgically
treated patients.15,16 In addition, for ease of interpretation,
some clinical variables were categorized into two groups,
leading to a loss of information to some extent. The response
rate of our study was satisfactory (83%) with a low likelihood
of introducing bias because the groups were comparable
regarding clinical pre- and postoperative variables. Although
survival was lower in the nonresponders (n  29) compared
with the responders (n 141), the difference was modest and
not significant (78 versus 82% at 3 years, p  0.12).
TABLE 1. Pre- and Postoperative Characteristics, Tumor
Stages, and Histopathology in Responders and Nonresponders
at 6 mo
Variables
Responders
(n  141),
Mean (SD) or
n (%)
Nonresponders
(n  29),
Mean (SD) or
n (%) p
Age (yr) 66.6 9.1 66.8 11.2 0.632
Women 76 54 11 38 0.153
Body mass index (kg/m2) 25.2 4.2 23.9 3.8 0.163
Ischemic heart disease 15 11 2 7 0.740
Hypertension 50 36 10 35 1.0
Congestive heart failure 1 1 1 3 0.313
Diabetes mellitus 13 9 2 7 1.0
Peripheral vascular disease 6 4 2 7 0.626
Cerebrovascular disease 4 3 4 14 0.030
Smoking status
Current smoker 56 40 18 62 0.039
Former smoker 65 46 9 31 0.154
Never smoker 20 14 2 7 0.375
Operation
Pneumonectomy 17 12 5 17 0.542
Lobectomy 117 83 24 83 1.0
Thoracotomy, sublobar
resection
5 4 0 0 0.590
VATS, sublobar resection 2 1 0 0 1.0
Adjuvant chemotherapy 51 36 8 28 0.521
Adjuvant radiotherapy 12 9 2 7 1.0
Atrial fibrillationa 7 5 3 10 0.377
Prolonged air leakb 12 9 2 7 1.0
Pneumonia 4 3 2 7 0.272
Hospital stay 8 d 23 16 14 48 0.001
Stage I 106 75 19 66 0.355
Stages II–III 35 25 10 34 0.355
Histopathology
Adenocarcinoma 94 67 23 79 0.270
Squamous cell carcinoma 20 14 2 7 0.375
Carcinoid 15 11 1 3 0.313
Other 12 9 3 10 0.723
a New onset.
b Chest tubes in place for more than 5 d.
SD, standard deviation; VATS, video-assisted thoracoscopic surgery.
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This study was not designed to investigate the reasons
underlying the association between quality of life parameters
and survival; therefore, further studies are needed to confirm
these findings and explore possible mechanisms. Patient-
reported outcomes (e.g., estimates of quality of life) have
consistently been linked to survival, and there may be several
possible explanations for this, as discussed by Gotay et al.1
Validated quality of life instruments, such as the SF-36, use
more sensitive response scales than other measures, and may
be able to detect relevant changes in patient health status
earlier than other measures. Perhaps patients’ own percep-
tions regarding functional, physical, or mental status are
closely correlated with survival. Another possibility is that
high quality of life has a direct influence on patients’ com-
pliance with recommended therapy, which may subsequently
confer improved survival.
Based on our data, we can speculate that self-reported
assessments of health-related quality of life offer a strong
indicator of long-term prognosis independent of important
clinical variables. The current British Thoracic Society
Guidelines on the radical management of patients with lung
cancer17 suggest using a global risk score, such as Thora-
coscore,18 to predict in-hospital death after general thoracic
surgery. If future studies corroborate our findings, quality of
TABLE 2. Associations between Baseline Short Form 36 Summary and Subscale
Scores and Survival in 170 Patients who Underwent Surgery for Lung Cancer
Variables
SF-36 Score Model 1a
Mean SD HRb 95% CI p
SF-36 summary scores
Physical component 45 11 0.958 0.932 to 0.985 0.003
Mental component 39 14 1.001 0.979 to 1.023 0.932
SF-36 subscale scores
Physical functioning 72 23 0.988 0.975 to 1.000 0.053
Physical role functioning 54 42 0.990 0.983 to 0.997 0.006
Bodily pain 74 27 0.992 0.981 to 1.003 0.142
General health 59 18 0.985 0.969 to 1.000 0.051
Vitality 56 24 0.996 0.984 to 1.008 0.494
Social functioning 70 27 0.989 0.979 to 0.999 0.033
Emotional role functioning 54 42 0.999 0.992 to 1.006 0.812
Mental health 59 25 1.001 0.989 to 1.013 0.876
a Adjusted for age, gender, comorbidities, extent of resection, tumor stage, smoking status, and postoperative
complications.
b Hazard ratio for 1 point difference in baseline Short Form 36 summary or subscale scores.
SF-36, Short Form 36; SD, standard deviation; HR, hazard ratio; CI, confidence interval.
TABLE 3. Short Form 36 Summary and Subscale Scores at Baseline and after 6 mo and
Associations between Survival and Changes in Short Form 36 Summary and Subscale Scores in
141 Patients who Underwent Surgery for Lung Cancer
Variables
Baseline
6 mo
Postoperative Change Model 2a
Mean SD Mean SD Mean SD HRb 95% CI p
SF-36 summary scores
Physical component 47 11 38 11 9 11 0.82 0.691 to 0.985 0.033
Mental component 39 13 43 13 4 15 0.87 0.787 to 0.973 0.014
SF-36 subscale scores
Physical functioning 74 22 62 25 12 24 0.72 0.606 to 0.855 0.001
Physical role functioning 60 40 30 40 29 42 0.92 0.820 to 1.034 0.164
Bodily pain 78 25 66 26 12 29 0.90 0.787 to 1.033 0.134
General health 62 18 55 21 7 19 0.74 0.600 to 0.924 0.008
Vitality 58 23 53 23 5 25 0.86 0.725 to 1.023 0.089
Social functioning 72 26 71 28 1 32 0.78 0.692 to 0.891 0.001
Emotional role functioning 56 42 52 45 5 48 0.93 0.852 to 1.018 0.116
Mental health 60 25 66 23 6 26 0.76 0.639 to 0.914 0.003
a Adjusted for age, gender, comorbidities, extent of resection, tumor stage, smoking status, postoperative complications, and corre-
sponding baseline SF-36 summary or subscale score.
b Hazard ratio for a 10% change in SF-36 summary scores or a 10-point change in SF-36 subscale scores.
SF-36, Short Form 36; SD, standard deviation; HR, hazard ratio; CI, confidence interval.
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life scores could possibly be used independently or in com-
bination with clinical variables in prediction models for
long-term survival after surgery for lung cancer.
In conclusion, we found that the baseline physical but
not mental aspects of quality of life were associated with
long-term survival after lung cancer surgery. Furthermore,
deterioration in either physical or mental quality of life from
baseline to 6 months after surgery was a significant risk factor
for mortality.
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